BACKGROUND: Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from t...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!